Hepatitis B virus-related hepatocelluar carcinoma
Conditions
Interventions
Case series:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Histopathological diagnosis of hepatocellular carcinoma; 2) Age 18-75 years old; 3) Expected survival time =3 months; Receive antitumor therapy. 4) Serum creatinine (Cr) =1.5×ULN and creatinine clearance(CCr)=50ml/min; 5) With his own consent and signed informed consent, voluntarily comply the planned visit, laboratory examination and other experimental procedures.
Exclusion criteria
Exclusion criteria: 1) In the past 5 years or at the same time have the history of other malignant tumors, except cured skin basal cell carcinoma and cervical carcinoma in situ, thyroid papillary carcinoma, etc.; 2) Patients with anti-tumor medications (herbal) (Chinese medicine with clear anti-tumor indications, such as compound plaque capsules) planned for 4 weeks prior to or during the study; 3) Active autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, dry syndrome, etc.) Corticosteroids required (equivalent dose of prednisone greater than 10mg per day) or other immunosuppressant subjects undergoing systemic therapy 4) have a history of immunodeficiency, including positive HIV tests, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation and bone marrow transplantation; 5) The subjects had hepatitis C (positive for hepatitis C antibodies, and HCV-RNA was higher than the lower limit of the analysis method); 6) History of psychotropic substance abuse, alcoholism and drug abuse; 7) History of severe mental disorders; 8) Patients who are lactating, pregnant; 9) There is a medical history, disease, treatment, or laboratory abnormality that may interfere with the results of the trial or prevent the participant from participating in the study throughout the course of the study, or the investigator does not believe that participating in the study is in the best interest of the subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA;AFP;TBNK cell count;Hepatitis B serologic testing; | — |
Countries
China
Contacts
Public ContactZhou Lingyun
West China Hospital of Sichuan University
Outcome results
None listed